TAK-925

Also Known As:

methyl (2R,3S)-3-(methanesulfonamido)-2-((4-phenylcyclohexyl)oxymethyl)piperidine-1-carboxylate

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Cataplexy 01/01/2023 - "TAK-925 and ARN-776 also reduced the cumulative amount of cataplexy during the 6 h post-dosing period. " 01/01/2023 - "All doses of TAK-925 and all but the lowest dose of ARN-776 eliminated cataplexy during the first hour after treatment; the anti-cataplectic effect of TAK-925 persisted into the second hour for the highest dose. "
2.	Disorders of Excessive Somnolence (Hypersomnia) 12/01/2019 - "TAK-925 may have therapeutic potential to reduce hypersomnia in multiple disorders including NT1."

1.	Aftercare (After-Treatment)